Intelligence Β· Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors β phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text β searchable for business development and competitive intelligence.
-
Sunvozertinib
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Potentially Resectable EGFR Exon 20 Insertion Non-Small Cell Lung Cancer
1 trial -
Surufatinib
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Biliary Tract Cancer
1 trial -
Systemic chemotherapy (FOLFIRI)
The First People's Hospital of Lianyungang
Rectum Cancer
1 trial -
TACE and HAIC Combined With Regorafenib
The First People's Hospital of Lianyungang
Liver Metastasis Colon Cancer
1 trial -
TACE with adebrelimab and bevacizumab
The First People's Hospital of Lianyungang
Adebrelimab
1 trial -
TAVR
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Aortic Valve Disease
1 trial -
TGRX-326
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Non-small Cell Lung Cancer
1 trial -
TNFΞ± Monoclonal Antibody
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Spinal Cord Injuries
1 trial -
TNTL capsule
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Accidental Exposure While Preparing Drug for Administration
1 trial -
TQB3616 Capsules Combined With Abiraterone Acetate Plus Prednisone
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Prostatic Neoplasms, Castration-Resistant
1 trial -
TRASTUZUMAB DERUXTECAN, SACITUZUMAB GOVITECAN
Ningbo Cancer Hospital
Patients with metastatic or locally advanced HER2-low triple-negative breast cancer and eligible to receive sacituzumab-govitecan and T-Dxd according to their indication.
1 trial -
TRASTUZUMAB, FULVESTRANT, EXEMESTANE, PERTUZUMAB, PERTUZUMAB, TRASTUZUMAB, PERTUZUMAB, TUKYSA 150 mg film-coated tablets, LETROZOLE, TUKYSA 50 mg film-coated tablets, TRASTUZUMAB, ANASTROZOLE
Ningbo Cancer Hospital
HER2+ metastatic breast cancer with isolated brain progression
1 trial -
TRASTUZUMAB, TRASTUZUMAB, TRASTUZUMAB EMTANSINE, TRASTUZUMAB, TRASTUZUMAB DERUXTECAN, PERTUZUMAB, TRASTUZUMAB EMTANSINE
Ningbo Cancer Hospital
Patients with HER2-positive locally advanced inoperable or metastatic breast cancer with disease controlled after 2 years of maintenance treatment with anti-HER2 targeted therapy
1 trial -
TS-1 with cisplatin
Hospital Authority, Hong Kong
Recurrent Gastric Cancer
1 trial -
TUKYSA 50 mg film-coated tablets, TUKYSA 150 mg film-coated tablets
Ningbo Cancer Hospital
Non-resectable locally advanced or metastatic HER2-positive breast cancer
1 trial -
Tacrolimus ointment
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Tacrolimus, Kaposiform Hemangioendothelioma, Tufted Angioma
1 trial -
Tangweian Recipe
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Diabetic Gastroenteropathy
1 trial -
Tas-102(Suyuan) combined with bevacizumab
The First People's Hospital of Lianyungang
Colorectal Cancer
1 trial -
Tecentriq 1 200 mg concentrate for solution for infusion
Ningbo Cancer Hospital
Muscle-invasive bladder cancer
1 trial -
Tecentriq 1,200 mg concentrate for solution for infusion, EXL01, IMFINZI 50 mg/mL concentrate for solution for infusion., Avastin 25 mg/ml concentrate for solution for infusion., Tecentriq 840 mg concentrate for solution for infusion, IMJUDO 20 mg/ml concentrate for solution for infusion., Avastin 25 mg/ml concentrate for solution for infusion.
Ningbo Cancer Hospital
Hepatocellular carcinoma
1 trial -
Tegafur Gimeracil Oteracil Potassium Capsule
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Breast Cancer
1 trial -
Telitacicept
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Connective Tissue Diseases
1 trial -
Telitacicept
The First People's Hospital of Lianyungang
Systemic Lupus Erythematosus
1 trial -
Temozolomide
The First People's Hospital of Lianyungang
Cytokine-Induced Killer Cells
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1β3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync β verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources